Geneos Wealth Management Inc. cut its stake in shares of DexCom, Inc. (NASDAQ:DXCM – Get Rating) by 8.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,479 shares of the medical device company’s stock after selling 657 shares during the quarter. Geneos Wealth Management Inc.’s holdings in DexCom were worth $847,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Centaurus Financial Inc. lifted its stake in shares of DexCom by 5.5% in the first quarter. Centaurus Financial Inc. now owns 1,236 shares of the medical device company’s stock worth $632,000 after buying an additional 64 shares during the last quarter. Fulton Bank N.A. grew its holdings in DexCom by 3.7% in the 4th quarter. Fulton Bank N.A. now owns 2,674 shares of the medical device company’s stock valued at $303,000 after buying an additional 95 shares during the last quarter. RMR Wealth Builders increased its position in DexCom by 1.8% in the 3rd quarter. RMR Wealth Builders now owns 5,442 shares of the medical device company’s stock worth $438,000 after buying an additional 98 shares during the period. Ascent Group LLC increased its position in DexCom by 2.1% in the 3rd quarter. Ascent Group LLC now owns 4,778 shares of the medical device company’s stock worth $577,000 after buying an additional 98 shares during the period. Finally, Jaffetilchin Investment Partners LLC boosted its position in shares of DexCom by 7.7% in the first quarter. Jaffetilchin Investment Partners LLC now owns 1,412 shares of the medical device company’s stock valued at $440,000 after acquiring an additional 101 shares during the period. 94.01% of the stock is currently owned by institutional investors and hedge funds.
DexCom Stock Up 1.3 %
Shares of NASDAQ DXCM opened at $116.28 on Friday. The company has a quick ratio of 1.83, a current ratio of 1.99 and a debt-to-equity ratio of 0.56. The company has a market cap of $44.93 billion, a price-to-earnings ratio of 143.56, a price-to-earnings-growth ratio of 2.71 and a beta of 1.16. DexCom, Inc. has a 12-month low of $66.89 and a 12-month high of $125.94. The firm’s 50-day simple moving average is $113.89 and its 200 day simple moving average is $110.08.
Analyst Upgrades and Downgrades
Several equities analysts recently commented on DXCM shares. Wolfe Research started coverage on shares of DexCom in a research note on Thursday, January 26th. They set an “outperform” rating and a $121.00 target price for the company. Morgan Stanley boosted their price target on DexCom from $117.00 to $131.00 and gave the company an “equal weight” rating in a research note on Friday, January 6th. Stifel Nicolaus raised their price objective on DexCom from $120.00 to $130.00 in a research report on Tuesday, December 20th. Cowen increased their price objective on shares of DexCom from $114.00 to $125.00 and gave the company an “outperform” rating in a research note on Friday, February 10th. Finally, Barclays upped their target price on shares of DexCom from $103.00 to $110.00 and gave the company an “equal weight” rating in a research note on Monday, February 13th. Three investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and a consensus price target of $124.06.
Insider Activity
In related news, EVP Barry J. Regan sold 2,213 shares of the business’s stock in a transaction that occurred on Monday, January 30th. The stock was sold at an average price of $106.12, for a total value of $234,843.56. Following the completion of the transaction, the executive vice president now directly owns 59,386 shares in the company, valued at approximately $6,302,042.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Barry J. Regan sold 2,213 shares of the stock in a transaction that occurred on Monday, January 30th. The stock was sold at an average price of $106.12, for a total value of $234,843.56. Following the completion of the sale, the executive vice president now owns 59,386 shares of the company’s stock, valued at approximately $6,302,042.32. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Sadie Stern sold 393 shares of the stock in a transaction that occurred on Monday, April 10th. The shares were sold at an average price of $112.35, for a total value of $44,153.55. Following the completion of the sale, the executive vice president now directly owns 83,252 shares of the company’s stock, valued at approximately $9,353,362.20. The disclosure for this sale can be found here. Insiders sold a total of 205,523 shares of company stock valued at $22,407,183 in the last ninety days. 0.41% of the stock is owned by insiders.
DexCom Profile
DexCom, Inc is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F.
Featured Articles
- Get a free copy of the StockNews.com research report on DexCom (DXCM)
- Delta Airlines Is Ready To Fly Higher
- Global Payments Climbs After Goldman Sachs Upgrade
- Fastenal Is At A Critical Turning Point
- 3 Healthcare Stocks Insiders Are Buying
- Novo Nordisk Charges Higher and Could be Just Getting Started
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.
